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A large scale community-based double blind randomized controlled trial was carried out in Chingleput district
of south India to evaluate the protective effect of BCG against bacillary forms of pulmonary tuberculosis.
From among 366,625 individuals registered, 281,161 persons were vaccinated with BCG or placebo by random
allocation. Two strains of BCG were used, the French and Danish, with a high dose (0.1mg/0.1ml) and a low
dose (0.01 mg/0.1 ml) in each strain. The entire population was followed up for 15 years by means of resurveys
every 30 months, and selective follow up every 10 months and continuous passive case finding. There were 560
cases (189,191 and 180 from the high dose, low dose and placebo groups respectively) arising over 15 years,
among 109,873 persons who were tuberculin negative and had a normal chest X-ray at intake. This represents
a small fraction of the total incidence of 2.6 per 1000 person-years most of which came from those who were
initially tuberculin positive. The incidence rates in the three “vaccination” groups were similar confirming the
complete lack of protective efficacy, seen at the end of 7% years. BCG offered no overall protection in adults
and a low level of overall protection (27%; 95% C.I. -8 to 50%) in children. This lack of protection could not be
explained by methodological flaws, or the influence of prior sensitisation by non specific sensitivity, or because
most of the cases arose as a result of exogenous re-infection. The findings at 15 years show that in this popula-
tion with high infection rates and high nonspecific sensitivity, BCG did not offer any protection against adult
forms of bacillary pulmonary tuberculosis.
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Tuberculosis remains one of the major health
problems in India accounting for one million new cases
every year. It is also the largest killer from a single major
pathogen in adult life. Among women, tuberculosis
accounts for as many deaths as maternal intrapartum
and postpartum complications. While adequate and
appropriate case management is an effective method of
controlling tuberculosis, the results of even a good
programme on reducing transmission rates will not be
felt for several decades since most of the transmission
would have occurred before detection of the case. Thus
 more effective method of interrupting transmission is
urgently required1. Vaccination with BCG is one possible
ethod of stopping or at least slowing down
tran mission, since BCG is expected to prevent
multiplication of bacilli in the body and prevent
development of new cases of tuberculosis even though
i  cannot prevent primary infection.
The vaccine prepared from the Bacillus Calmette-
Guerin has been in use for over 5 decades in the
prevention of tuberculosis and indeed has been routinely
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used for tuberculosis control in several countries. It iscons dered important to test some of these hypotheses,
not only an extensively used but also the mostand o look for protection offered by BCG in the later
extensively studied vaccine and has been the subject ofyears. Moreover, the number of cases occurring among
prolonged and bitter controversy over its efficacy. Eightthose initially tuberculin negative, particularly in the
major community-based prospective, controlled trialsyounger age groups was small. Therefore, it was decided
have been carried out to establish its efficacy. Theto continue the follow up for a longer period. The present
observed levels of protection have ranged from 0-80report deals. with the findings of the trial after 15 years
per cent2. Several factors, including the methodologicalof follow up in those who were initially negative to
issues3,4 have been postulated to explain the variationtuberculin. The efficacy of BCG in the tuberculin
in protective efficacy, but none of them has been whollypositives has been briefly reported in the earlier report8
satisfactory. and are not dealt with here.
A study in south India5 had shown that BCG could
protect only to the level of 31 per cent. However, the
sample size in that study was small. It was felt, therefore,
that a reliable estimate of the protective effect of BCG
in this country was required, in order that its usefulness
as a public health measure may be determined. It was
against this background that the trial of tuberculosis
prevention in south India6 was designed with the
objectives of obtaining (i) a precise estimate of the
protective effect of BCG vaccination against
tuberculosis in the non-infected; (ii) the protective effect
of BCG vaccination in persons already infected; (iii) th
protective effect of two different strains of BCG; and
(iv) the influence of dosage of BCG on the protective
effect. This study was expected to provide a conclusive
answer with regard to the protective efficacy offered by
BCG. For this reason, there were two expert committees
that went into the possible issues that may obfuscate
the interpretation of the results of the study. One dealt
with vaccine related issues7, and the other with the
design of the study and the field operations (unpublished
report: Indian’ Council of Medical Research, Expert
Committee on the Tuberculosis Prevention Trial,
Madras, 1977). Both committees concluded that there
were no reasons related either to the vaccine or to the
conduct of the study, that could throw any doubt on the
results of the study when they became known. The
preliminary results of the study were published at the
end of 7½ years. This showed that “BCG does not
protect against bacillary pulmonary tuberculosis”8,9.
This unexpected finding evoked a great deal of scientific
interest, and several reasons were postulated for the lack
of protection10. These issues were such that they could
not be discussed even in the detailed report of the study
published at 7½ years6 since decoding of denominators
had been deferred till the end of the trial. It was
Material & Methods
The trial of BCG vaccines in south India was carried
out in a largely rural community with some semiurban
areas. It was a large community-based double blind
randomized controlled study. Two vaccine strains, one
Danish and the other French, were evaluated against a
placebo control, and within each strain, two doses were
evaluated; 0.1 mg/0.1 ml (high dose) and 0.01 mg/0.1
ml (low dose). All individuals aged one month or more
in the study area, which covered 209 panchayats and 9
town blocks, irrespective of the tuberculin status were
allocated randomly to receive vaccine or placebo, such
that one third of subjects received placebo, one third
the Danish and one third the French strain. Half the
individuals (randomly selected) in each of the vaccine
groups received a high dose and the other half a low
dose. Randomization was at the individual level and
not by cluster. The total population in the study area
who received the “vaccine” was 281,161 among whom
there were 117,718 who were classified as “uninfected”,
i.e., those showing a reaction size of 7mm or less to
3 IU of purified protein derivative (PPD-S) of
mammalian tuberculosis. Analysis of protective efficacy
was restricted to this latter group.
The details of the methodology, the basis for
selection of vaccine strain and the basis for definitions
of infection and disease have been presented in detail
earlier6,8,9. A brief summary of the field work and
analysis methods is presented here.
At intake, all individuals were registered on
indivi ual cards and those aged 1 yr and above were
tested with both 3 IU of PPD-S and 10 units of
mycobactin prepared from Battery strain (PPD-B),
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randomly allocated to either forearm. At the time of
testing, all individuals aged one month or more were
given, by random allocation, either high dose or low
dose of the vaccine or a placebo. Vaccine strains Danish
1331 and French 1173 P2 were used. Vaccine and
placebo were supplied to the project staff in coded
ampoules. The codes were retained at the headquarters
of the Indian Council of Medical Research and were
not available to any of the project staff. Rigorous steps
were taken to ensure that the cold chain was not broken.
To facilitate identification of each individual over the
entire trial period, finger prints were taken on the back
of the card on which the vaccine code was entered.
Case finding was almost continuous. All individuals
aged 5 yr and above were screened by mass miniature
radiography once every 30 months (regular surveys).
All “suspects”(those with abnormal X-ray),
symptomatics and absentees in the regular surveys were
X-rayed once in 10 months (selective follow up). To
identify cases occurring between these surveys, a
network of passive case finding centres were established
in the Government run peripheral health institutions i.e.,
primary health centres (PHC) in the area where
individuals with symptoms who self reported could be
examined for tuberculosis. The medical officers of these
institutions referred the symptomatics to the trial staff.
These persons were X-rayed using an MMR
(GENERAY, Italy) machine which was taken to the PHC
at least once a week. These methods were expected to
maintain a continuous surveillance and pick up almost
all the cases occurring in the study area. Each round of
examination (resurvey or selective followup) was
concluded only after obtaining at least 90 per cent
coverage.
All X-rays were read independently by two readers,
who were unaware of the identity of the individual or
the vaccine group to which he/she belonged. In case of
disagreement in X-ray reading between the readers, X-
rays were submitted to a third (“umpire”) reader. One
spot and one overnight specimens of sputum were
collected from each individual whose X-ray was read
as abnormal by either reader and subjected to smear for
acid fast bacilli (AFB) and culture for Myc bacterium
tuberculosis. Finger prints were again taken at the time
of sputum collection. The identification of the individual
from whom the specimen was collected was not
available to the bacteriologist.
Case-status was objective and very rigourously
defin d. Only those who were culture positive on at least
one specimen of sputum were regarded as cases of
tuberculosis for estimating the protective efficacy of
BCG vaccination. The scar status, tuberculin status or
the vaccination status were not considered in defining a
“case”.
The study was started in 1968 and intake phase was
completed by 1971. Fifteen years follow up was
completed in September 1987.
Statistical methods: Once a “case” was defined, the fin-
ger prints taken at the time of sputum collection were
compared with those at intake to ensure identity. Since
only 52 per cent of the total population remained at the
end of the study period, denominators were defined in
terms of person-years. If a person was seen at least once
during one round of examination (resurvey or selective
follow up or passive case finding) he or she was con-
sidered to have contributed 2½ person-years to the study.
The incidence was calculated from the total number of
cases occurring in each round divided by the number of
person-years of observation in the round. Protective
efficacy was calculated from the formula 100 (1-RR),
where RR is the risk ratio, obtained from the ratio of
incidence among the vaccination and the placebo
groups. Confidence intervals were calculated using ap-
propriate formulae11.
The “vaccinated” cohort considered for analysis is
those with 0-7 mm reaction size to PPD-S and normal
chest X-ray at intake. Persons less than 10 yr of age at
int ke were ineligible for X-ray. It was assumed that
these persons were normal on chest X-ray.
Results
Epidemiological characteristics of the study area: The
study area selected included 209 contiguous panchayats
and one town, from Thiruvellore and Thiruttani tal ks
in Chingleput district, Tamil Nadu, south India. A de-
tailed description of the study area along with the base-
line characteristics has been reported previously6. The
overall prevalence of tuberculosis infection was 54 per
cent in males and 46 per cent in females with an annual
risk of infection of 4.1 per cent. The prevalence and
incidence (over the first 2½ years) of bacillary disease
was 1055 per 100,000 and 250 per 100,000 per annum
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respectively6. These characteristics were examined over
15 years, to document the trend of the disease over the
duration of the study period.
Prevalence of culture positive cases, at each of the 7
rounds, is shown in Table I. The prevalence of bacillary
disease has come down from 1055 per 100,000 to 775
per 100,000 over 15 years. In males, this decrease has
been from 1655 to 1307, and in females from 454 to
250 per 100,000. The age distribution was uniform over
the years.
The incidence of culture positive cases over 15 years
(Table II) has also shown a decline from 383 to 232 per
100,000 per year; from 576 to 361 and from 187 to 102
per 100,000 per year, in males and females respectively.
During the first round of follow up, 94 and 92 per cent
of new cases in males and females respectively came
from those initially infected, i. ., those showing a
reaction size of 12 mm or more to PPD-S. This
proportion showed a decline over the years; but even
so, during the sixth round of follow up, 80 per cent of
new cases in males and 78 per cent of new cases in
females came from those initially infected (Table III).
Base-line characteristics of the study population: Since
th  allocation of individuals to the three groups, 0.1 mg
of BCG, 0.01 mg of BCG and Placebo, was at the indi-
vidual level, it was expected that the distribution of per-
sons allocated to the three groups would be similar with
respect to various known and unknown factors. The dis-
tribution of persons in the three groups according to
some important factors is shown in Table IV. The num-
ber of persons allocated to each of the three groups was
similar with over 93,000 persons in each group. The
age distribution of the individuals and the proportion of
males and females was similar in each group. This simi-
larity was also maintained in the three groups with re-
spect to initial tuberculin status. Equal number of indi-
viduals had been allotted to the “Danish” and the
“French” strains. Thus the three groups were similar
with respect to age, sex, initial tuberculin status and
strain of vaccine used.
Coverages: The entire population was surveyed seven
times using the same techniques. At each survey, the
coverage of the available population was over 90 per
cent. However, the numbers in the original cohort of
individuals included for “vaccination” declined. These
Table I. Prevalence of culture positive cases at rounds I-VII
Age Prevalence (rate per 100,000) at round
group,
yr I II III IV V VI VII
Males
10-24 226 179 146 113 180
25-44 1934 1787 1908 1629 1588
45+ 3613 3818 3869 3719 3490
10+ 1655 1634 1675 1528 1484
(37519) (42788) (44449) (49479) (51303)
Females
10-24 124 120 80 95 85
25-44 546 449 485 421 310
45+ 867 642 792 790 430
10+ 454 364 396 377 249
(37386) (41710) (44347) (49225) (5 1359)
Both sexes
10-24 176 150 113 104 134
25-44 1206 1085 1162 996 918
45+ 2306 2307 2405 2325 2034
10+ 1055 1000 1037 953 868
(74905) (84498) (88796) (98704) (102662)
Standardised rates calculated on the basis of the age-sex distribution of population at round I
Figures in parentheses give number X-rayed
151 79
1606 1369
3389 3248
1454 1307
(53032) (52729)
89 59
256 331
574 399
262 250
(54138) (55283)
120 69
898 825
2050 1893
859 775
(107170) (108012)
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Age
group,
yr I-II
Table II. Incidence of culture positive cases
Incidence (rate per 100,000) at round
II-III III-IV IV-V V-VI VI-VII
Males
10-24 137 118 73 103
25-44 627 639 417 418
45+ 1270 1012 736 747
10+ 576 511 350 365
(29463) (3263 1) (35196) (38655)
Females
10-24 57 66 41 43
25-44 231 166 145 107
45+ 317 326 263 145
10+ 187 165 133 92
(29072) (32432) (35792) (38850)
Both sexes
10-24 100 94 58 75
25-44 413 383 270 250
45+ 814 684 509 459
10+ 383 339 242 230
(58535) (65063) (70988) (77505)
Standardised rates calculated on the basis of the age-sex distribution of population at round I
Figures in parentheses give number X-rayed
65 83
449 403
767 787
365 361
(40033) (40103)
37 35
125 132
215 156
113 102
(41243) (42634)
52 61
274 256
503 485
240 232
(81276) (82737)
Table III. Incidence of culture positive cases, according to size of reaction to PPD-S at round I (Age group: 5+ yr)
Reaction Incidence (rate per 100,000) at round
to PPD-S
(Round I) I-II II-III III-IV IV-V V-VI VI-VII
0-11 mm 36 55
(30817) (30730)
12+mm 554 445
(35708) (29191)
% of cases 94 89
with 12+ mm
Figures in parentheses give number X-rayed
Males
62
(16139)
481
(14544)
87
109
(15263)
538
(13863)
83
34
(15451)
145
(11937)
81
109
(13975)
582
(12591)
84
36
(13562)
202
(10954)
85
73
(27537)
405
(23545)
85
156
(12415)
617
(11351)
80
59
(1 1623)
208
(10067)
78
109
(24038)
425
(21418)
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losses were similar in the three groups, as can be seen
from Table V. On an average, 11 per cent had either
died or migrated by 2% years, 17 per cent by 5 years,
22 per cent by 7½ years; 28 per cent by 10 years, 35 per
cent by 12½ years and 42 per cent by 15 years. Thus, at
the 7th round, 52 per cent of the cohort was examined,
7 per cent had died, 35 per cent had migrated and 6 per
cent absented themselves for the X-ray examination.
Case finding: Most of the cases were diagnosed at the
time of resurveys where the whole population was X-
rayed. However, a proportion of the population (about
10%) was re-X-rayed during selective follow up, in or-
der to diagnose cases arising out of those who were
“suspects” in the resurvey rounds. Similarly, symptom-
atic individuals seeking treatment between the rounds
(about 2%) were investigated at the passive case find-
ing centres. Similar numbers of individuals were ex-
amined at each round by each of these methods in the
three groups. There was no difference in diagnostic
methods employed between the three groups as can be
Table IV. Base-line characteristics of the study population
Factor 0.1 mg of BCG0.01 mg of BCG Placebo
Age, yr :
1m-4 11350 (12.16) 11413 (12.22) 11497 (12.18)
5-9 13138 (14.08) 13187 (14.11) 13165 (13.94)
10-14 12615 (13.52) 12724 (13.62) 12911 (13.67)
15-24 15508 (16.62) 15564 (16.66) 15593 (16.51)
25-44 25181 (26.99) 25110 (26.88) 25496 (27.00)
45+ 15520 (16.63) 15433 (16.52) 15757 (16.69)
Sex :
Males 47247 (50.63)47514 (50.85)48039 (50.88)
Females46065 (49.37)45917 (49.15)46379 (49.12)
Strain of BCG :
Danish 47241 (50.63)47039 (50.39)47625 (50.44)
French 46071 (49.37)46392 (49.65)46793 (49.56)
Tuberculin status (mm) :
0-7 39681 (42.53) 39012 (41.75) 39025 (41.33)
8-15 14212 (15.23) 14297 (15.30) 14459 (15.31)
16+ 35723 (38.28) 36415 (38.98)37220 (39.42)
Absent 3696 (3.96) 3707 (3.97) 3714 (3.93)
Total 93312 (100.00)93431 (100.00)94418 (100.00)
Figures in parentheses give percentages to total
Period of
Table V. X-ray coverages over 15 years
0.1 mg of BCG 0.01 mg of BCG Placebo
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seen from Table VI. Thus the three groups were similar
with respect to susceptibility (base-line characteristics),
surveillance and diagnostic testing (case-finding).
Protective efficacy of BCG: Protective efficacy was cal-
culated from among those who were considered tuber-
culin negative (i.e., reaction size of 0-7 mm to PPD-S)
at intake and infants- who were assumed to be non-
reactors. Those who had normal chest X-ray, or were
ineligible for X-ray were considered as non-cases at
intake. A new (incidence) case is defined as an indi-
vidual with an abnormal X-ray, who has produced at
least one positive culture on sputum examination. The
incidence of new cases by vaccination status from
among these persons in each time period is shown in
Table VII.
It was seen that in the first 5 years after vaccination,
the average annual incidence of tuberculosis was higher
in the vaccinated groups as compared to that in the
placebo group. In the next 7½ years, there was some
evidence of protection with a higher incidence of disease
in the placebo group as compared to that in the group
receiving the high or the low dose of BCG. Between
12½ to 15 years, however, there was again an increase
in the annual rates among the vaccinated as compared
to that among those receiving the placebo. Considering
the entire period of follow up, however, there was no
difference in the attack rate of tuberculosis in the three
groups, the average annual rates being 50, 51 and 48
per 100,000 in the high dose, low dose and placebo
groups respectively. The differences within each period,
in favour of, or against the vaccine were not statistically
significant, except for low dose BCG in the second
Table VI. Percentage of total examined in the three “vaccine” groups
for each of three case finding methods over 15 years
Period of
follow up,    “Vaccine”
yr group
% of total examined in each of
Resurvey SelectivePassive
follow up follow up follow up
0 - 2.5
2.5 - 5
5 - 7.5
7.5 - 10
10 - 12.5
12.5 - 15
0.1 mg BCG
0.01 mg BCG
Placebo
0.1 mg BCG
0.01 mg BCG
Placebo
0.1 mg BCG
0.01 mg BCG
Placebo
0.1 mg BCG
0.01 mg BCG
Placebo
0.1 mg BCG
0.01 mg BCG
Placebo
0.1 mg BCG
0.01 mg BCG
Placebo
33.8
33.1
33.1
(82152)
33.6
33.2
33.2
(82009)
33.7
33.1
33.2
(77322)
33.7
33.2
33.1
(69882)
33.7
33.1
33.2
(63616)
33.7
33.2
33.2
(549 14)
35.6
32.4
32.0
(3399)
33.4
33.0
33.5
(11039)
34.4
32.8
32.8
(11205)
34.1
33.5
32.4
(9333)
33.8
33.4
32.7
(5172)
34.0
34.2
31.8
(6397)
Figures in parentheses give total examined
34.4
34.6
31.0
(1161)
36.3
32.7
31.2
(1489)
34.9
31.9
33.2
(2137)
34.7
32.2
33.1
(1884)
34.1
33.2
32.7
(1457)
33.9
33.7
32.4
(1201)
Table VII. Annual incidence by vaccination status for all ages
Period of 0.1 mg of BCG 0.01 mg of BCG Placebo
follow up,
yr Person- No. of Person- No. of Person- No. of
years cases years cases years cases
0 - 2.5 76675 11 (14) 75298 14 (19) 75348 6 (8)
2.5 - 5 70955 23 (32) 70125 34(48) 69993 12 (17)
5 - 7.5 67710 25 (37) 66478 17 (26) 66620 29 (44)
7.5 - 10 61797 34 (55) 60702 35 (58) 60603 46 (76)
10 - 12.5 55238 35 (63) 54202 44(81) 54272 46 (85)
12.5 - 15 48070 61 (127) 47468 47(99) 47142 41 (87)
0- 15 380445 189 (50) 374273 191 (51) 373978 180 (48)
Figures in parentheses give average annual rate per 100,000
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period. Thus, the overall protection, for all ages, must
be taken to be nil.
Although the estimated protective efficacy for all
ages over 15 years was nil, the possibility that BCG
may offer some protection in children was examined
(Table VIII). It is seen that in children aged 1 month to
4 yr, the protective efficacy is of the order of 32 and 18
per cent respectively for the high and low doses of BCG,
and in children aged 5 to 9 yr, it is 24 and 23 per cent;
i.e., in children aged 1 month to 9 yr, a moderate
protective efficacy of 27 and 21 per cent is seen with the
high and low doses of BCG respectively. However, these
levels of protection were not statistically significant with
the limits of the confidence intervals lying on either
side of zero. In age groups 10- 14 yr and above, the attack
rates in those who received either dose of vaccine is
slightly higher as compared to that in those who received
the placebo, except for low dose of BCG in age group
10-14 yr. None of these differences were statistically
significant.
The protective efficacy of BCG in children, aged 1
month to 9 yr, was examined by period of follow up, by
comparing the incidence rates of tuberculosis in the
vaccinated and placebo groups (Table IX). The pattern
of results in these children is similar to that seen among
persons of all ages. The incidence rate among those
vaccinated with either dose of BCG in the first five years
of follow up was higher than that in those receiving
placebo; these differences were not statistically
significant. Subsequently upto 12½ years, the incidence
rates in the placebo group was much higher (P<0.01)
as compared to that in the vaccinated groups, suggesting
a protection of 69 per cent with the high dose and 59
per cent with the low dose. Between 12½ to 15 years,
the incidence rates in the vaccinated group were again
higher than that in the placebo group; these differences
were not statistically significant. Nevertheless. over
15 years, the average annual rates were 20, 22 and 27
per 100,000 in those receiving the high dose, low dose.
or placebo respectively resulting in a marginal protection
of 27 per cent with the high dose and 21 per cent with
the low dose BCG respectively. However, as the
confidence intervals are wide, and lie on either side of
zero, the ‘protection’ seen in this age group must be
interpreted with caution.
Table VIII. Protective efficacy of BCG vaccine by age
Age
0.1 mg of BCG 0.01 mg of BCG Placebo Prot. effect (%)
group,
yr
Person- No. of
years cases
Person-
years
No. of
cases
Person-
years
No. of
cases
0.1 mg 0.01 mg
of BCG of BCG
(95% CI) (95% CI)
15s-24 41378 49 40420
(118)
25-34 28365 23 25775
(81)
35+ 28785 28 28270
45 38960 34
(111) (87)
29 26115 20
(113) (77)
35 28090 24
(97) (124)
Total 380445 189 374273 191
(50) (51)
a Figures in parentheses give average annual rate per 100,000
b 95% confidence interval
(85)
373978 180
(48)
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Protective efficacy according to strain of BCG: The
overall protection by BCG, for all ages, was seen to be
nil (Table VII). The very remote possibility of one strain
being associated with a protective and the other with a
harmful effect was examined. As no such difference was
observed the results of both strains have been combined.
It was also examined whether the moderate protective
effect seen among children, aged 1 month to 9 yr, was
similar with the two strains (Table X, upper half). With
the high dose of BCG, the protective efficacy was 27
per cent for either strain (P>0.9), and with the low dose
of BCG, it was 25 per cent for Danish strain and 17 per
cent for French strain (P>0.7), the levels of protection
in all four instances being statistically not significant.
Thus, the two strains behaved similarly in the children
studied.
Influence of non-specific sensitivity: Influence of prior
exposure to environmental mycobacteria on the protec-
tive effect of BCG was examined (Table X, lower half).
A reaction size of 10 mm or more (reactors) to PPD-B
is taken to indicate prior exposure to environmental
mycobacteria6. Only children are included in this analy-
sis, as the proportion of adults who are non-reactors to
Table IX. Annual incidence by vaccination status in children aged 1 month to 9 yr
Period of 0.1 mg of BCG 0.01 mg of BCG Placebo
follow up,
yr Person- No. of Person- No. of Person- No. of
years cases years cases years cases
0 - 2.5 43790 5 (11) 43305 6 (14) 43555 3 (7)
2.5 - 5 41390 7 (17) 41112 9(22) 41388 3(7)
5 - 7.5 39465 3 (8) 39150 3 (8) 39528 12 (30)
7.5 - 10 36153 6 (17) 36000 6 (17) 36078 8 (22)
10 - 12.5 31995 3 (9) 31833 7 (22) 31862 19 (60)
12.5 - 15 26782 20 (75) 26930 16 (59) 26842 15 (56)
0 - 15 219575 44 (20) 218330 47 (22) 219253 60 (27)
Figures in parentheses give average annual rate per 100,000
Table X. Influence of strain of BCG and non-specific sensitivity on protective efficacy
(a) Strain of BCG :
Danish strain
0.1 mg 0.01 mg
of BCG of BCG
Placebo
Prot. effect (%)
0.1 mg 0.01 mg
of BCG of BCG
Person-years
No. of cases
French strain
110620 108725 109315 27 25
23 23 31 (-26,57) (-28, 57)
Person-years 108955
No. of cases 21
(b) Non-specific sensitivity :
0-9 mm to PPD-B
109605 109938 27 17
24 29 (-28, 58) (-43, 52)
Person-years
No. of cases
10+mm to PPD-B
125985 122268 122313 39 12
20 28 32 (-6, 65) (-45.47)
Person-years 93590 96062 96940 11 32
No. of cases 24 19 28 (-53.49) (-23, 62)
Figures in parentheses give 95% confidence limits
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PPD-B is very small. With the high dose of BCG, the
protective efficacy was 39 per cent among the non-re-
actors (0-9 mm to PPD-B) and 11 per cent among the
reactors (P>0.2), and with the low dose of BCG, it was
12 per cent among the non-reactors and 32 per cent
among the reactors (P>0.2). In all four instances the
confidence intervals were wide, and included zero, the
levels of protection being statistically not significant.
Thus the protective efficacy is not influenced by prior
exposure to environmental mycobacteria as measured
by size of reaction to PPD-B.
Also, i f  prior exposure to environmental
mycobacteria was protective, the attack rates in the
reactors should be much less than that in the non-
reactors, at least in the placebo group, where there has
been no interference with BCG. It is seen, however, that
the attack rates among the reactors is 28.9 per 100,000
as compared to 26.2 per 100,000 in the non-reactors
(P >0.7). This is contrary to what is expected if prior
non-specific sensitization offered protection.
Discussion
Chingleput was chosen as the study area for the BCG
trial since the area had a high incidence of tuberculosis
as well as a high prevalence of sensitivity to non-
tuberculous mycobacteria; in addition BCG was not a
current Public Health measure. This report presents the
findings of the trial after 15 years of follow up. BCG
has offered no overall protection in adults and a low
level of overall protection (27%; 95% C.I.: -8% to 50%)
in children.
The tendency for excess cases among the vaccinated
seen in the first five years reappears at 12½ to 15 years
in contrast to the finding of fewer cases in the vaccinated
between 5 and 12½ years. The same trends are seen
even in those who were less than 10 yr old at intake.
The varying pattern of results by period of follow up
seen in this trial was also observed in the BCG trial at
Madanapalle, south Indias. More cases were seen among
the vaccinated during the first three years, thereafter up
to the 9th year fewer cases were seen among the
vaccinated indicating protection by BCG, and during
the last two to three periods the incidence among the
vaccinated was higher than that among the controls. The
authors explain that the vaccinated cases occur later than
the unvaccinated and that the group of vaccinated
persons continue to produce cases when the
corresponding controls have ceased to do so. In the
British BCG trial12, it was observed that in the sixth
period of observation, .e. from 12½ to 15 years, and
beyond, the incidence of cases among the vaccinated
was higher than that among the unvaccinated controls
contrary to what was seen in the earlier periods. A
gradual increase in the level of resistance in the
unvaccinated group and a gradual decrease in the level
of resistance in the vaccinated groups are given as
possible reasons.
The estimates of protective efficacy are based on
rates per 100,000 person-years obtained from complete
decoding of the trial population. They need to be
evaluated taking into account several criticisms and
hypotheses that have been put forward after the
publication of the earlier report at 7½ years.
Clemens et al3 have suggested that methodological
flaws could account for the variations in the observed
efficacy levels of protection by BCG observed in the
various trials. They cited four main sources of bias,
namely, susceptibility bias, surveillance bias, diagnostic
testing bias and diagnostic interpretation bias, and
suggested that the Chingleput trial might have suffered
from the first three. Such issues could not be addressed
earlier as the trial was ongoing and the key to the vaccine
codes was not available with the project staff. With
complete decoding, however, it has become obvious
(Tables IV-VI) that the study population was equally
distributed between the three groups with respect to
base-line characteristics that could have influenced the
development of tuberculosis. The coverages of the
population available at each round were similar for the
three groups, as also the proportion of the original cohort
available for follow up at each round. The proportion
of d ad and those who had migrated were also very
similar for the three groups. Thus biases in allocation
(susceptibility) and surveillance (differential follow up
of the groups) could not have operated in the trial. Three
methods were used for case detection which ensured
tha  almost all cases arising in the area would have been
registered. The number of persons examined at each
round by each of these methods was equally distributed
betwe n the three groups. The trial covers a large
population, in fact the largest among the reported
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community trials of BCG efficacy, which has been
systematically and meticulously followed up for 15
years with bias free management (the trial was kept
double blind) and objective definitions of case
(bacteriological confirmation) in order to avoid
diagnostic testing bias. The trial was designed to detect
a difference of 50 per cent with 80 per cent power, based
on the assumption that the prevalence of bacillary
disease in the area would be about 4 per 1000. However,
it was seen that the prevalence was actually 11 per 1000,
about 1½ times the expected value. Thus, a re-
examination of the trial size showed that the sample
size of the trial was large enough to detect a vaccine
efficacy of 50 per cent (even among the subgroups).
It is thus unlikely that methodological flaws or lack
of power could account for the lack of protection seen
in the trial. This has been endorsed by a committee of
experts convened by the WHO and the ICMR in Madras
in 1977 before the analysis of results was begun. This
committee reviewed carefully both the design and the
field procedures and concluded that there were no
obvious deficiencies that could influence the resultsof
the trial (unpublished report: Indian Council of Medical
Research, Expert Committee on the Tuberculosis
Prevention Trial, Madras, 1977).
The vaccine strains have been evaluated carefully,
both prior to selection and during the vaccination phase,
and were found to produce good post vaccination
allergy. The evidence regarding lack of influence by
strain variation has been discussed at length in previous
report6,8,9. The consensus appears to be that strain
differences or variations, or mutations in the strains used,
could not have contributed to the lack of protective
efficacy. In vitro tests and animal experiments (VC) have
shown that there were no differences in the strains used.
The high prevalence of non-specific sensitivity is
another factor that is invoked as a reason for the lack of
protection by BCG10. It is argued that environmental
mycobacteria have sensitizing properties similar to those
of BCG and that BCG does nothing to add to this prior
protection. This hypothesis is suggested by the findings
in mice13 and guineapigs14 in which challenge with a
variety of non-tuberculous mycobacteria (NTM)
induced protection and late immunization with BCG
could not improve on this protection. These results were
confirmed more recently by Narayanan et al 15. This
hypothesis would appear to be plausible given the fact
that NTM were isolated from 8.6 per cent of sputum
pecimens collected from the study area16. If this were
tru  in humans and BCG does indeed have some
protective efficacy, this should be seen in those who
wer  initially non-reactors to PPD-B, in whom the
pos ible protection offered by BCG would not be
“masked” by prior exposure to environmental
mycobacteria. The data, however, show that even in
children below 10 yr of age who were initially not
reacting to PPD-B, the protective efficacy, with both
doses of BCG, was only marginal and not statistically
significant. Also, the protective efficacies seen among
non-reactors to PPD-B did not differ significantly from
those seen among reactors to PPD-B. Further, if
exposure to environmental mycobacteria could afford
protection, then there should be substantially less cases
among those who were initially infected with such
mycobacteria. Such protection is also not seen (Table
X); in the placebo group, in children reacting with 0-7
mm to PPD-S, the attack rate (28.9 per 100,000) among
“reactors” to PPD-B was similar to that (26.2 per
100,000) seen among “non-reactors” to PPD-B. Similar
findings are seen in the study in Puerto Rico17,18 where
the same low protection (31%) was seen in those positive
and those negative to the high dose test. Thus, it seems
unlikely that non-specific mycobacteria could have
mask d the effect of BCG if the later had indeed been
protective in human beings.
BCG is not expected to offer protection against
exogenous reinfection. Since Chingleput is known to
be an area with a high prevalence of tuberculosis, it has
been hypothesized that most of the disease that occurred
in the study population, was a result of exogenous
reinfection and that this could be a reason why BCG
had failed to show protection in the study area. It has
been suggested19 that if most of the disease was from
endogenous reactivation, then a great proportion of new
cases arising in the study area would come from those
initially infected. The data (Table III) show that even
after 15 years, 80 per cent of cases have come from
among those who were found infected (12 mm or more
to PPD-S) at intake. It has also been suggested20 that if
the disease was due to endogenous reactivation, the
proportion of new cases with INH resistance would
probably remain constant over the years and would be
substantially less than that among all prevalence cases.
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In this area, the prevalence of INH resistance has
remained steady over the years even in fresh cases (Table
XI). There is no significant difference in the trend. When
this is seen in conjunction with the fact that the
proportion of new cases occurring from the initially
infected has declined only very slightly from 94 to 80
per cent over 15 years, it is possible that most of the
cases occur due to endogenous reactivation. Though this
is indirect epidemiological evidence, it would appear
that exogenous reinfection could not have contributed
to a significant proportion of disease and masks a
protective efficacy due to BCG, if such an effect had
indeed been present. However, whether a given case
has occurred as a result of endogenous reactivation or
exogenous reinfection is very difficult to decide.
Genetic differences in human ethnic groups leading
to different mechanisms of action of BCG in different
races was postulated as yet another reason why BCG
failed to show any protection in this population.
Investigations carried out by the Tuberculosis Research
Centre show that no significant differences in the
patterns of macrophage induced killing of M .
tuberculosis was found between Indian and British
subjects either before or after BCG vaccination21,22.
This trial was designed to test the value of BCG as a
public health measure, i.e., in cutting down transmission
of tuberculosis. This potential benefit of BCG needs to
be reviewed in the light of the epidemiology of
tuberculosis in the study area and in other parts of India.
The study area is characterised by high infection rates
in children and high disease rates in middle aged and
older people. Unlike in Britain12 most of the disease
(94 to 80%) came from those who were infected rather
than uninfected initially. The pattern of incidence is
similar in Madanapalle23 and Bangalore24 where 75 and
65 per cent of the burden of disease, respectively, was
contributed by those initially infected. Thus even if BCG
offered protection in those initially uninfected (which
it does not) the public health value of BCG can be only
in preventing childhood mortality caused by disease
resulting from haematogenous spread. The impact on
infectious cases can at best be only minimal. Styblo
and Meijer25 examining the impact of BCG vaccination
programmes in children and young adults on the
tuberculosis problem, have shown that the impact of
Table XI. Resistance to INH of culture positive cases over 15 yr
Round Prevalence cases Incidence cases
of
examination no. % resistant no. % resistant
I 707 12.7 -
II 729 18.4 519 5.8
III 792 21.5 481 10.8
IV 884 15.4 409 5.6
V 824 20.1 423 10.9
VI 873 21.2 457 10.7
VII 776 21.4 443 10.8
Resistant to INH : MIC >1µg/ml
such vaccination on the incidence in persons aged over
30 yr, is “not readily discernible”. Rodrigues and Smith26
arrived at similar conclusions after reviewing the
efficacy of BCG and the epidemiology of tuberculosis
in several geographical regions. Sutherland1 has rgued
that a policy of BCG vaccination among infants or
adolescents cannot prevent disease in older individuals
who would have already been infected and hence can
have no impact on transmission.
The impact of BCG vaccination on childhood forms
of tuberculosis was not investigated in the Chingleput
trial. This was probably because, BCG was expected to
reduce the risk of transmission by reducing the sputum
positive cases and this was rare in children. Since the
publication of the 7½ year report, this question has been
extensively investigated by the World Health
Organisation27,28. The protection has ranged from 0-95
per cent with case-control studies and less than 50 per
cent from contact studies. Observational studies
generally suffer from biases which may even be
undetectable. Not withstanding this, the efficacies
reported have repeated the pattern seen in the
community-based studies.
In conclusion, the Chingleput trial, which was
designed to evaluate BCG as a public health measure,
has shown that BCG offers no protection against adult
type bacillary tuberculosis. Consequently, BCG cannot
be expected to reduce the transmission due to
tuberculosis. This observation of failure to protect, could
not be attributed to defects in methodology, inadequate
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sample size, prior exposure to environmental
mycobacteria or to most of the disease being a result of
exogenous reinfection. These unexpected results have
led to several studies which would eventually increase
our understanding of the host responses and immune
mechanisms in tuberculosis.
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